NonExomics
NonExomics is a privately held medicinal genomics company that uses a cloud-deployed machine-learning platform integrating multi-omics data to discover noncanonical protein drug targets across 1,365 human diseases, serving pharmaceutical, biotech, and academic clients via licensing and collaboration agreements.
- Company typePrivate
- Founded2016
- HeadquartersActon, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What NonExomics does
NonExomics, Inc. is a medicinal genomics company that has built an 8+ year, cloud-deployed machine-learning platform integrating genomics, transcriptomics, proteomics, structural genomics, and biochemical/biophysical methodologies to discover and validate noncanonical proteins — proteins it claims are generated from the entire human genome rather than just the canonical 1–2% gene region. The platform has reportedly validated under 250,000 noncanonical proteins and identified under 3,000 novel drug targets associated with 1,365 human diseases, with experimental validation of druggability across multiple targets using modalities including small molecules, antisense oligos, antibodies, and gene therapy.
The company monetizes through a partnership-driven model: it licenses its noncanonical protein target portfolio to pharma and biotech for drug development, runs collaborative target-identification and validation services for biotech, pharma, and academic clients, and offers companion-diagnostics co-development for rare-disease and oncology patient stratification. Pricing is bespoke and not publicly disclosed; the distribution channel is direct enterprise sales of collaboration agreements, supported by scientific publications and earned media rather than traditional marketing.
NonExomics was founded in 2016 as NonExomics, LLC by Ruchi Chauhan and Sudhakaran Prabakaran (later joined by serial bio-instrumentation entrepreneur Gary Magnant) and reincorporated in 2021 as NonExomics, Inc. The company is headquartered in Boston, with operations in Cambridge, UK (where Prabakaran ran an academic lab from 2016 to 2021) and indicated activity in India. It is privately held, venture-backed, employs 1–10 people, and is currently in early-stage commercialization with only a pre-seed round and an Illumina Accelerator investment disclosed to date.
NonExomics firmographics
Firmographics- Name
- NonExomics
- Legal name
- NonExomics, Inc.
- Website
- https://nonexomics.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NonExomics is a privately held medicinal genomics company that uses a cloud-deployed machine-learning platform integrating multi-omics data to discover noncanonical protein drug targets across 1,365 human diseases, serving pharmaceutical, biotech, and academic clients via licensing and collaboration agreements.
- Ownership category
- akta.pro rank
NonExomics industry classification
Industry- Product category
- Drug Target Discovery / Medicinal Genomics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industries
- Companion Diagnostics (CDx) Development & Commercialization (HLAAANAC), Companion Diagnostics (CDx) Development & Trial Testing Support (HLAGAEAJ)
Keywords
Where NonExomics is headquartered
LocationHeadquarters
- HQ city
- Acton
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
NonExomics business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Target Licensing and Partnership Deals: NonExomics generates revenue by licensing their discovered noncanonical protein targets to pharmaceutical and biotech companies for drug development. The company seeks partnerships to advance treatments through clinical trials.
- Target Identification Services: Collaborative services for biotech companies, pharmaceutical companies, and academia to identify disease-specific targets using the NonExomics platform. Targets are validated experimentally for further preclinical validations.
- Companion Diagnostics Development: Partnership opportunities for companion diagnostics identification in drug co-development process, including diagnosis and patient stratification for rare diseases and cancer.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NonExomics product offering
Product offeringCore offering
NonExomics develops a proprietary, patent-pending machine learning platform that integrates genomics, transcriptomics, proteomics, and structural biology to identify druggable noncanonical proteins from the entire human genome. The company sells target identification services, licensing of novel drug targets, and companion diagnostics collaboration to pharmaceutical companies, biotech firms, and academic institutions. Its portfolio includes under 3,000 novel targets associated with 1,365 human diseases.
Product overview
NonExomics operates as a medicinal genomics company with a unified platform approach centered on decoding the dark genome. The core NonExomics Dark Genome Analysis Platform integrates genomics, transcriptomics, proteomics, and AI methodologies to identify druggable noncanonical proteins from the entire human genome. This platform is supported by three complementary service offerings: Target Identification Services for disease-specific collaboration, Therapeutic Modality Collaboration for validating targets across small molecules, antisense oligos, antibodies, and gene therapy, and Companion Diagnostics for patient stratification and drug co-development. Together, these services address a portfolio of approximately 3000 novel targets associated with 1365 human diseases.
Differentiator
Problem solved
Functional benefit
Products and services
- NonExomics Dark Genome Analysis Platform A proprietary and patent-pending platform that integrates genomics, transcriptomics, proteomics, and AI methodologies to identify druggable noncanonical proteins from the entire human genome, including the 98% previously considered non-coding.
- Target Identification Services Collaborative service with biotech companies, pharmaceutical companies, and academia to identify disease-specific targets using the NonExomics platform, with experimental validation for preclinical studies.
- Therapeutic Modality Collaboration Partner engagement offering to validate prioritized targets using small molecules, antisense oligos, antibodies, and gene therapy approaches.
- Companion Diagnostics Discovery service to identify companion diagnostics for drug co-development, including patient diagnosis and stratification for rare diseases and cancer.
Quantifiable outcome
- Demonstrated that 10x more proteins exist than previously known, enabling understanding of difficult-to-treat diseases
- +2 more outcomes
Companies that use NonExomics
Customer profileSegments4 records
Ideal customer profiles4 records
NonExomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
NonExomics partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and minor.
- University of CambridgecoreNonExomics originated from research conducted at the University of Cambridge. Co-founder Sudhakaran Prabakaran ran his academic lab in the Department of Genetics at Cambridge. The company licensed dark genome research from Cambridge and continues academic collaborations.
- Undisclosed Partner OrganizationsminorNonExomics has forged two undisclosed partnerships for target validation and preclinical development. The company is actively seeking additional partnership opportunities.
Scale indicators6 records
Recent moves5 records
Expansion highlights5 records
NonExomics competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: Recursion is an AI-driven drug-discovery platform that integrates high-throughput biology with machine learning to identify novel therapeutic targets and develop small-molecule candidates. It is directly comparable to NonExomics in using ML + multi-omics to expand the target universe, though Recursion focuses on phenotypic screening rather than noncanonical proteins.
- Insitro: Insitro combines machine learning with functional genomics and induced pluripotent stem cell biology to discover and validate novel drug targets. Like NonExomics, it positions itself as a target-discovery platform selling partnerships to pharma, and competes for the same ML-multi-omics-capital narrative.
- Schrödinger: Schrödinger operates a computational chemistry and biology platform used by pharma to discover targets and design molecules, with a software-plus-services business model. It is comparable to NonExomics as a platform selling computational discovery into pharma pipelines, though at a far more mature stage.
- Verge Genomics: Verge uses ML on human multi-omics data — including genomics and transcriptomics from patient tissue — to identify new therapeutic targets, with an emphasis on neuroscience. It directly parallels NonExomics' ML + multi-omics approach and its emphasis on difficult-to-treat neurological disease.
- BenevolentAI: BenevolentAI applies AI to biomedical knowledge graphs and omics data to identify novel targets and reposition existing drugs. It is comparable to NonExomics as an AI-driven target-identification partner for pharma, particularly in complex diseases where traditional target discovery has underperformed.
- Owkin: Owkin is an AI-biotech that uses multimodal patient data (genomics, transcriptomics, histology) to discover biomarkers, targets, and companion diagnostics, often partnering with academic medical centers. Its data-driven target and CDx discovery model closely resembles NonExomics' target identification + companion diagnostics offering.
Broad incumbents
- Foundation Medicine: Foundation Medicine (a Roche subsidiary) is a leading molecular diagnostics and companion-diagnostics company whose genomics platform identifies patient-specific alterations to guide therapy selection. It is comparable to NonExomics as a CDx and genomic-target-discovery player, but at much greater scale and with established pharma partnerships.
- 10x Genomics: 10x Genomics provides single-cell and spatial omics instrumentation and consumables used widely in target-discovery and translational research workflows. It is comparable as an enabling technology provider in the multi-omics discovery stack that NonExomics' platform depends on, though it sells tools rather than targets.
- SomaLogic: SomaLogic operates a large-scale proteomics platform (SomaScan) measuring thousands of proteins for biomarker and target discovery, partnering with pharma and academic researchers. It is comparable to NonExomics in scaling proteomic measurement for novel protein target identification, though SomaLogic focuses on known-protein quantification rather than noncanonical discovery.
- Exscientia: Exscientia is an AI-driven precision medicine company combining target identification with end-to-end small-molecule drug design. It is comparable to NonExomics as a pharma-partnered AI drug-discovery platform, though Exscientia is more advanced in clinical assets and platform commercialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights6 records
Customer concentration
NonExomics social profiles
Digital presenceNonExomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
NonExomics leadership team
Management profileNumber of profiles
Profiles3 records
NonExomics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NonExomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NonExomics
What does NonExomics do?
NonExomics develops a proprietary, patent-pending machine learning platform that integrates genomics, transcriptomics, proteomics, and structural biology to identify druggable noncanonical proteins from the entire human genome. The company sells target identification services, licensing of novel drug targets, and companion diagnostics collaboration to pharmaceutical companies, biotech firms, and academic institutions. Its portfolio includes under 3,000 novel targets associated with 1,365 human diseases.
Is NonExomics a public or private company?
NonExomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was NonExomics founded?
NonExomics was founded in 2016. It employs 1 to 10 people.
Where is NonExomics based?
NonExomics is headquartered in Acton, United States, in the North America region.
How does NonExomics make money?
Three revenue lines are on record. Target Licensing and Partnership Deals are the primary driver. The others are target Identification Services and companion Diagnostics Development.
Who are NonExomics's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Schrödinger, Verge Genomics, BenevolentAI and Owkin. Broad incumbents are Foundation Medicine, 10x Genomics, SomaLogic and Exscientia.
Does NonExomics have an API?
No public API is recorded for NonExomics.
What industry is NonExomics in?
NonExomics's product category is Drug Target Discovery / Medicinal Genomics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAANAC, Companion Diagnostics (CDx) Development & Commercialization. Its NAICS code is 541714 and its SIC code is 8731.